Williams Rodney James

Director Williams Rodney James bought 100,000 ZOM shares at $0.07 on 2025-03-17; stock now $0.10 (-44.4% from 52-week high). Cluster activity.

Director Williams Rodney James purchased 100,000 shares at $0.07, increasing his holdings by 61.8% to 261,900 shares. The purchase occurred at a significant discount to the 52-week high of $0.18, with the stock currently trading at $0.10. This acquisition is part of a cluster pattern with 7 other insiders buying within the past 14 days, suggesting coordinated confidence at depressed levels. However, context matters: Zomedica is unprofitable with net income of $-6,697,000.00 against quarterly revenue of $6,997,000.00, and the stock has declined 18.6% over 30 days and 22.7% over 90 days, indicating persistent negative momentum despite the insider buying signal.

Director Rodney James buys 100,000 shares of ZOM at $0.07; 7 insiders bought within 14 days as stock trades -44.4% from 52-week high

Rodney James, a director, purchased 100,000 shares at $0.07 on 2025-03-17, his first transaction in ZOM and only his second documented open-market buy across all tickers. The stock is currently trading at $0.10, representing -44.4% from its 52-week high of $0.18. Most notably, this buy is part of a coordinated cluster pattern: 7 other insiders also bought within the past 14 days, suggesting alignment among the board or management regarding valuation at depressed levels. The company remains unprofitable (net income $-6.7M in the latest quarter against $7.0M revenue), which contextualizes the stock's steep decline and raises questions about whether the cluster buying reflects confidence in a turnaround or opportunistic accumulation at a distressed valuation.